Markets:

Overview

News

Currencies

International

Treasuries

Ironwood Pharmaceuticals, Inc. - Class A Common Stock (NQ:IRWD)

3.865 -0.135 (-3.37%)

Streaming Delayed Price Updated: 11:38 AM EDT, Jul 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ironwood Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Ironwood to Present New Data at Digestive Disease Week® 2023 Demonstrating Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old

April 24, 2023

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Host First Quarter 2023 Investor Update Call

April 20, 2023

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Participate in Upcoming Investor Conferences

February 27, 2023

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Earnings Scheduled For February 16, 2023 ↗

February 16, 2023

Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year...

Via Benzinga

Earnings Outlook For Ironwood Pharmaceuticals ↗

February 15, 2023

Via Benzinga

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results

February 16, 2023

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of Supplemental New Drug Application for LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old

February 13, 2023

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

3 No-Brainer Stocks to Buy Right Now for Less Than $25 ↗

February 04, 2023

All three healthcare stocks are showing solid long-term potential.

Via The Motley Fool

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Investor Update Call

February 02, 2023

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Why Ironwood Pharmaceuticals Shares Are Falling During Monday's Session ↗

January 09, 2023

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) shares are trading lower by 10.00% to $11.30 Monday afternoon after the company cut its FY22 sales guidance below analyst estimates and issued FY23 sales...

Via Benzinga

Ironwood Pharmaceuticals Provides Update on FY 2022 Financial Guidance and Announces FY 2023 Financial Guidance

January 09, 2023

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 04, 2023

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Participate in the Piper Sandler 34th Annual Healthcare Conference

November 22, 2022

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals: Q3 Earnings Insights ↗

November 03, 2022

Ironwood Pharmaceuticals (NASDAQ:IRWD) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Ironwood Pharmaceuticals Reports Strong Third Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance

November 03, 2022

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Host Third Quarter 2022 Investor Update Call

October 20, 2022

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Shares Positive Top-line Data From Late-Stage Functional Constipation Candidate Study In Patients Aged 6-17 Years ↗

September 06, 2022

Ironwood Pharmaceuticals (NASDAQ: IRWD) announced positive top-line data from its Phase 3 clinical trial evaluating LINZESS (linaclotide) 72 mcg in pediatric patients aged 6-17 with functional...

Via Benzinga

Ironwood's Constipation Drug Shows Efficacy In Pediatric Patients ↗

September 06, 2022

Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) announced topline data from a Phase 3 trial evaluating Linzess (linaclotide) 72 mcg in pediatric patients aged 6-17 with functional constipation.

Via Benzinga

Ironwood Pharmaceuticals Reports Positive Topline Data from Phase III Trial of LINZESS® (linaclotide) in Pediatric Patients Aged 6-17 with Functional Constipation

September 06, 2022

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Present at the 2022 Wells Fargo Healthcare Conference

September 01, 2022

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Wells Fargo Maintains Equal-Weight Rating for Ironwood Pharmaceuticals: Here's What You Need To Know ↗

August 16, 2022

Wells Fargo has decided to maintain its Equal-Weight rating of Ironwood Pharmaceuticals (NASDAQ:IRWD) and raise its price target from $12.00 to $13.00. Shares of Ironwood Pharmaceuticals are trading...

Via Benzinga

Ironwood Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guidance Due to Continued Strength of LINZESS® Prescription Demand

August 04, 2022

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Host Second Quarter 2022 Investor Update Call

July 21, 2022

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

5 Value Stocks In The Healthcare Sector ↗

July 18, 2022

What is a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators...

Via Benzinga

The Daily Biotech Pulse: Third FDA Rejection For Verrica's Skin Disease Drug, Assembly Bio Terminates Hepatitis B Virus Pact, Consistency Data For Valneva's Chikungunya Vaccine ↗

May 25, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Ironwood Presents New Data Demonstrating Potential of IW-3300 for Visceral Pain at Digestive Disease Week® (DDW) 2022

May 25, 2022

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Present New IW-3300 and Linaclotide Data at Digestive Disease Week® 2022

May 09, 2022

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals: Q1 Earnings Insights ↗

May 05, 2022

Ironwood Pharmaceuticals (NASDAQ:IRWD) reported its Q1 earnings results on Thursday, May 5, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Ironwood Pharmaceuticals Reports First Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance

May 05, 2022

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Q1 2022 Earnings Conference Call On May 5, 2022 At 08:30 AM ET ↗

April 29, 2022

Ironwood Pharmaceuticals (NASDAQ:IRWD) will host a conference call at 08:30 AM ET on May 5, 2022, to discuss Q1 2022 earnings results.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.